164 related articles for article (PubMed ID: 26589470)
1. Minimum mycophenolic acid levels are associated with donor-specific antibody formation.
Filler G; Todorova EK; Bax K; Alvarez-Elías AC; Huang SH; Kobrzynski MC
Pediatr Transplant; 2016 Feb; 20(1):34-8. PubMed ID: 26589470
[TBL] [Abstract][Full Text] [Related]
2. What is the intrapatient variability of mycophenolic acid trough levels?
Todorova EK; Huang SH; Kobrzynski MC; Filler G
Pediatr Transplant; 2015 Nov; 19(7):669-74. PubMed ID: 26201386
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
Pape L; Ehrich JH; Offner G
Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Study on Mycophenolic Acid Drug Interactions: Effect of Prednisone, Sirolimus, and Tacrolimus With MPA.
Alvarez-Elías AC; Yoo EC; Todorova EK; Singh RN; Filler G
Ther Drug Monit; 2017 Jun; 39(3):220-228. PubMed ID: 28437284
[TBL] [Abstract][Full Text] [Related]
5. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.
Theruvath TP; Saidman SL; Mauiyyedi S; Delmonico FL; Williams WW; Tolkoff-Rubin N; Collins AB; Colvin RB; Cosimi AB; Pascual M
Transplantation; 2001 Jul; 72(1):77-83. PubMed ID: 11468538
[TBL] [Abstract][Full Text] [Related]
6. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
[TBL] [Abstract][Full Text] [Related]
7. Trough Level of Mycophenolic Acid Did Not Affect De Novo DSA Development in Kidney Transplantation.
Masaki N; Iwadoh K; Tonsho M; Koyama I; Nakajima I; Fuchinoue S
Transplant Proc; 2019 Oct; 51(8):2624-2628. PubMed ID: 31563242
[TBL] [Abstract][Full Text] [Related]
8. Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation.
Caillard S; Becmeur C; Gautier-Vargas G; Olagne J; Muller C; Cognard N; Perrin P; Braun L; Heibel F; Lefebre F; Renner V; Gachet C; Moulin B; Parissiadis A
Transpl Int; 2017 Jan; 30(1):29-40. PubMed ID: 27678382
[TBL] [Abstract][Full Text] [Related]
9. Donor-specific antibodies in a pediatric kidney transplant population-Prevalence and association with antiproliferative drug dosing.
Strommen AM; Moss MC; Goebel J; Bock M
Pediatr Transplant; 2019 Sep; 23(6):e13511. PubMed ID: 31168879
[TBL] [Abstract][Full Text] [Related]
10. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
11. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
12. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[TBL] [Abstract][Full Text] [Related]
13. Developmental changes of MPA exposure in children.
Yoo EC; Alvarez-Elías AC; Todorova EK; Filler G
Pediatr Nephrol; 2016 Jun; 31(6):975-82. PubMed ID: 26743220
[TBL] [Abstract][Full Text] [Related]
14. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
Narumi S; Watarai Y; Goto N; Hiramitsu T; Tsujita M; Okada M; Futamura K; Tomosugi T; Nishihira M; Sakamoto S; Kobayashi T
Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
[TBL] [Abstract][Full Text] [Related]
17. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
18. Determinants of mycophenolic acid levels after renal transplantation.
Borrows R; Chusney G; James A; Stichbury J; Van Tromp J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
Ther Drug Monit; 2005 Aug; 27(4):442-50. PubMed ID: 16044100
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
Solomon S; Colovai A; Del Rio M; Hayde N
Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
[TBL] [Abstract][Full Text] [Related]
20. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
